Analysts Set Catalyst Biosciences Inc (CBIO) PT at $23.88

Catalyst Biosciences Inc (NASDAQ:CBIO) has received a consensus recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $23.88.

Several research firms have weighed in on CBIO. Zacks Investment Research cut shares of Catalyst Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. Chardan Capital reissued a “buy” rating and issued a $35.00 price target on shares of Catalyst Biosciences in a report on Thursday, December 20th. CIBC assumed coverage on shares of Catalyst Biosciences in a report on Friday, January 4th. They issued an “outperform” rating and a $24.00 price target on the stock. Finally, Oppenheimer assumed coverage on shares of Catalyst Biosciences in a report on Friday, January 4th. They set an “outperform” rating and a $24.00 target price on the stock.

Several hedge funds and other institutional investors have recently bought and sold shares of CBIO. Dimensional Fund Advisors LP raised its stake in shares of Catalyst Biosciences by 150.1% during the third quarter. Dimensional Fund Advisors LP now owns 404,358 shares of the biopharmaceutical company’s stock valued at $4,359,000 after acquiring an additional 242,705 shares during the last quarter. National Asset Management Inc. raised its stake in Catalyst Biosciences by 40.0% during the fourth quarter. National Asset Management Inc. now owns 35,000 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 10,000 shares during the last quarter. Wells Fargo & Company MN raised its stake in Catalyst Biosciences by 47.2% during the third quarter. Wells Fargo & Company MN now owns 50,397 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 16,165 shares during the last quarter. BlackRock Inc. raised its stake in Catalyst Biosciences by 3.9% during the third quarter. BlackRock Inc. now owns 807,441 shares of the biopharmaceutical company’s stock worth $8,704,000 after buying an additional 30,437 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Catalyst Biosciences by 2,029.9% during the third quarter. JPMorgan Chase & Co. now owns 66,196 shares of the biopharmaceutical company’s stock worth $714,000 after buying an additional 63,088 shares during the last quarter. Institutional investors and hedge funds own 62.70% of the company’s stock.

Catalyst Biosciences stock opened at $8.85 on Friday. Catalyst Biosciences has a twelve month low of $6.20 and a twelve month high of $29.95.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.16). As a group, research analysts expect that Catalyst Biosciences will post -3.79 EPS for the current year.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.